<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130801</url>
  </required_header>
  <id_info>
    <org_study_id>21-225</org_study_id>
    <nct_id>NCT05130801</nct_id>
  </id_info>
  <brief_title>A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery</brief_title>
  <official_title>Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP® ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Instruments</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>pHLIP Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether pre-operative mpMRI using additional MRI&#xD;
      sequences may improve surgical outcomes by providing more accurate information about the&#xD;
      extent and acidity of the tumor than standard MRI, and to see whether the use of the&#xD;
      fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that&#xD;
      may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more&#xD;
      clearly and remove them completely.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>15 days post pHLIP® ICG injection</time_frame>
    <description>is defined as a clinically significant adverse event recorded within 3 hours after pHLIP® ICG administration or an abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, surgery, or concomitant medications, and meets the NCI common terminology criteria that are CTCAE Grade 3 or 4.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MRI and pHLIP® ICG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants in Phase I will receive pre-operative MRI and mpMRI scans, a pre-operative injection of pHLIP ICG, and NIRF imaging during surgery (intra-operatively). During phase IIa of the study, if pHLIP® ICG NIRF imaging indicates tumor in areas outside of the planned resection area, biopsy samples will be taken from these areas and submitted for pathological analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pHLIP® ICG NIRF imaging</intervention_name>
    <description>Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).&#xD;
In Phase I, we propose to investigate 4 different doses:&#xD;
Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg</description>
    <arm_group_label>MRI and pHLIP® ICG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 years or greater&#xD;
&#xD;
          -  Biopsy proven primary breast malignancy (BI-RADS 6)&#xD;
&#xD;
          -  Tumor stage T1 and T2, lesion size &gt; 1 cm&#xD;
&#xD;
          -  Primary surgical treatment with breast conservation&#xD;
&#xD;
          -  No previous treatment&#xD;
&#xD;
          -  No contraindications for MRI or MRI contrast agents or high-field MRI (3T)&#xD;
&#xD;
          -  ECOG performance of 0-2&#xD;
&#xD;
          -  Liver function laboratory test results within the normal institutional reference range&#xD;
             (AST (Plasma &lt;=37 U/L); ALT (Plasma &lt;=55U/L); Albumin (Plasma 3.8-5.0 g/dL); Bilirubin&#xD;
             (total Plasma &lt;=1.2mg/dL); Creatinine (0.6-1.1 mg/dL))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known contrast agent allergies that require premedication before MRI.&#xD;
&#xD;
          -  Patients who cannot undergo multiparametric MRI scanning because of:&#xD;
&#xD;
               -  Weight limits. MRI scanners may not be able to function with patients over 450&#xD;
                  pounds.&#xD;
&#xD;
               -  Severe claustrophobia/ examination associated anxiety.&#xD;
&#xD;
               -  MRI unsafe implant&#xD;
&#xD;
          -  Known metastatic liver disease, hepatic neoplasms (benign and malignant), biliary&#xD;
             atresia, chronic liver disease (CLD) and cirrhosis.&#xD;
&#xD;
          -  Known moderate hepatic impairment (in phase I, and in phase IIa dependent on safety&#xD;
             profile established in phase I)&#xD;
&#xD;
          -  Known hypersensitivity to indocyanine green.&#xD;
&#xD;
          -  Individuals with impaired-decision making capacity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast Cancer</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Pinker-Domenig, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katja Pinker-Domenig, MD, PhD</last_name>
    <phone>646-888-5470</phone>
    <email>pinkerdk@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Morrow, MD</last_name>
    <phone>646-888-5350</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Pinker-Domenig, MD, PhD</last_name>
      <phone>646-888-5470</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>pHLIP® ICG</keyword>
  <keyword>Imaging</keyword>
  <keyword>Tumor stage T1-T2</keyword>
  <keyword>21-225</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

